Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study

BACKGROUND: Ustekinumab (UST), a newly-used biologic targeting p40 subunit of IL12 and IL23 in China, exerts a confirmed therapeutic effect on the induction and maintenance therapies for refractory Crohn’s disease (CD). Therapeutic drug monitoring based on trough and antibody concentration is of cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Jia-yin, Zhang, Min, Wang, Wei, Peng, Xiang, Zhao, Jun-zhang, Liu, Tao, Li, Zhi-wei, Sun, Hai-tian, Hu, Pinjin, Zhi, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522105/
https://www.ncbi.nlm.nih.gov/pubmed/34663208
http://dx.doi.org/10.1186/s12876-021-01946-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522105/
https://www.ncbi.nlm.nih.gov/pubmed/34663208
http://dx.doi.org/10.1186/s12876-021-01946-8

Ejemplares similares